NL-OMON31913已完成3 期
An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essential hypertension when given a light meal - SPP2405
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •The mean sitting systolic blood pressure should be between 150 and 180 mm Hg mercury at randomisation (visit 3).
排除标准
- •Severe hypertension (mean sitting diastolic blood pressure above or equal 110 mm Hg and/or mean sitting systolic blood pressure above or equal 180 mm Hg.
研究者
相似试验
进行中（未招募）
不适用
An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essential hypertension when given with a light mealhypertensionEUCTR2008-001305-42-FRovartis Pharma Services AG744
进行中（未招募）
不适用
An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essential hypertension when given with a light meal - NDESSENTIAL HYPERTENSIONMedDRA version: 9.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2008-001305-42-ITOVARTIS FARMA744
进行中（未招募）
1 期
An eight-week double-blind, multi-center, randomized,placebo-controlled, parallel-group study to evaluate theefficacy and safety of aliskiren 75mg, 150mg and 300mg inelderly patients with essential hypertension when givenwith a light mealhypertensionEUCTR2008-001305-42-ISovartis Pharma Services AG744
进行中（未招募）
不适用
An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essential hypertension when given with a light mealhypertensionEUCTR2008-001305-42-SKovartis Pharma Services AG744
进行中（未招募）
不适用
An eight-week double-blind, multi-center, randomized,placebo-controlled, parallel-group study to evaluate theefficacy and safety of aliskiren 75mg, 150mg and 300mg inelderly patients with essential hypertension when givenwith a light mealhypertensionEUCTR2008-001305-42-CZovartis Pharma Services AG744